[Diabetes-talk] Foot Care

[Frye, Dan]

List Colleagues:
 
We have received the following announcement here at the National Center
for the Blind. It was submitted with the hope of having it published in
the Voice of the Diabetic. Since this magazine is no longer being
produced, I am sharing this information with those of you subscribed to
this list. I cannot endorse or say that I know anything at all about the
product referenced in the following release; I have not edited the
language. Knowing little about Diabetes except that which I am now
learning, I will regularly share such information as I receive, which
would have been otherwise directed to the Voice of the Diabetic staff,
particularly where it seems possibly important to the community. On
occasion materials such as this may also be published in the Braille
Monitor. If you have received information about this product through
other avenues, please forgive the duplicate circulation. The
announcement follows:
 
 
Ortho Dermatologics

--------------------------------

 

 

For immediate release

 

Contact:

     Maureen Pratscher

     847/382-7404

 

     Andrew Huff

     847/382-7404




  

Ortho Dermatologics Launches Educational Initiative for Professionals
and Their Patients

LOS ANGELES (March 18, 2009) -- Ortho Dermatologics (formerly
OrthoNeutrogena) has introduced an innovative online educational program
for health professionals and their patients to provide information about
tinea pedis and the use of Ertaczo(R) (sertaconazole nitrate) cream, 2%,
in treating this widespread disorder.

Tinea pedis, commonly known as athlete's foot, is estimated to affect 70
percent of Americans during their lifetime.  Ertaczo is a novel,
broad-spectrum antifungal agent that is both efficacious and well
tolerated.  The active ingredient in Ertaczo, sertaconazole nitrate, has
been shown, in vitro, to be more effective than other antifungal agents
against the key tinea-causing dermatophytes: Trichophyton rubrum, T.
mentagrophytes and Epidermophyton floccosum.

The new Web-based initiative, located at www.ertaczo.com
<BLOCKED::http://www.ertaczo.com/> , features comprehensive educational
sections and support materials for professionals and patients,
respectively.  The professional section includes information on tinea
pedis, its differential diagnosis and the common co-morbidities of
onychomycosis and diabetes, as well as Ertaczo.  Product information
covers the fungicidal, anti-inflammatory and antipruritic properties as
well as full prescribing information and a special resource center to
order product samples and patient education materials. 

The patient section provides in-depth consumer background on the causes
and symptoms of athlete's foot, the use of Ertaczo and proper care to
prevent recurrence.  Through a cost-saving rebate form, patients can
save up to $50 on a 60-g tube or up to $25 on a 30-g tube of Ertaczo. 

Health care professionals will also find a direct link to a Web-based
educational initiative called TheFungalLink.com, with video
presentations by key opinion leaders in the dermatology and podiatric
communities on clinical insights and recent research on the management
of fungal infections such as tinea pedis. 

"It's not only important for health professionals to have ready access
to the most current information on the treatment of tinea pedis, but
patient compliance is important as well," said Dr. Lee Rogers, director
of the Amputation Prevention Center in Des Moines, Iowa.  "This new Web
program makes a significant contribution toward both of these goals."

When not treated properly, tinea pedis may be a significant medical
issue.  Tinea pedis may be a precursor to onychomycosis, in which
infection can then spread to surrounding skin.  This may be a particular
concern in patients with diabetes, who may develop bacterial cellulitis
and/or lymphangitis.  Tinea pedis can also lead to increased
complications in individuals with peripheral vascular disease and in
elderly patients. 

In clinical trials, cutaneous adverse events occurred in 2 percent of
patients receiving Ertaczo and in 2 percent of patients receiving
vehicle.  These reported adverse events included contact dermatitis, dry
skin, burning skin, application site reaction and skin tenderness. 

Ertaczo is distributed and marketed by Ortho Dermatologics, a division
of Ortho-McNeil Pharmaceutical, Inc.

# # #

09DD0049

 

 

With Kind Regards,

 

 

***********************
Daniel B. Frye, J.D.
Associate Editor
The Braille Monitor
National Federation of the Blind
Office of the President
1800 Johnson Street
Baltimore, Maryland 21230
Telephone: (410) 659-9314 Ext. 2208
Mobile: (410) 241-7006
Fax: (410) 685-5653
Email: DFrye at nfb.org
Web Address: www.nfb.org <http://www.nfb.org/> 
"Voice of the Nation's Blind"